Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome
https://doi.org/10.33667/2078-5631-2019-2-13(388)-52-56
Abstract
The high prevalence of metabolic syndrome in population has led to the cholelithiasis is important problem of modern health care along with coronary heart disease, arterial hypertension and diabetes. The main role in the formation of gallbladder pathology in patients with metabolic syndrome belongs to insulin resistance, atherogenic dyslipidemia, and non‑alcoholic fatty liver disease. Тhe prescription of ursodeoxycholic acid is pathogenetically justified. This article presents modern views on the mechanisms formation of gallstone disease in the conditions of metabolic disorders and management of this patients based on the results own research.
About the Authors
V. A. Akhmedov
Omsk State Medical University
Russian Federation
Omsk
Russian Federation
Omsk
O. V. Gaus
Omsk State Medical University
Russian Federation
Omsk
Russian Federation
Omsk
References
1. Stinton L. M., Stinton E. A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012; 6 (2): 172–187.
2. Jessri M., Rashidkhani B. Dietary patterns and risk of gallbladder disease: a hospital-based case-control study in adult women. Journal of Health, Population and Nutrition. 2015; 33 (1): 39–49.
3. Буеверов А. О. Хронические заболевания желчного пузыря и желчевыводящих путей: Краткое руководство для практикующих врачей. Москва; 2015.
4. Di Ciaula A., Wang D. Q., Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert. Rev. Gastroenterol. Hepatol. 2019; 13 (2): 157–171.
5. Ahmed M. J., Mahmood R., Rana R. S. et al. Metabolic Syndrome: An Indicator of Complicated Gall Stone Disease? Cureus. 2018; 10 (11): e3659.
6. Ильченко А. А., Делюкина О. В. Клиническое значение билиарного сладжа. Consilium medicum. 2005; 7: 134–137.
7. Гаус О. В., Ахмедов В. А. Влияние метаболического синдрома на состояние паренхимы печени и билиарной системы у пациентов с желчнокаменной болезнью. Уральский медицинский журнал. 2015; 1 (124): 132–137.
8. Biddinger S. B., Haas J. T., Yu B. B. et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat. Med. 2008; 14 (7): 778–782.
9. Ильченко А. А., Долгашева Г. М. Ожирение как фактор риска неалкогольной жировой болезни желчного пузыря (холецистостеатоза, стеатохолецистита). Экспериментальная и клиническая гастроэнтерология. 2009; 8: 80–93.
10. Ахмедов В. А., Гаус О. В. Поражение органов гепатобилиарной системы и поджелудочной железы при ожирении. Терапевтический архив. 2017; 89 (1): 128–133.
11. Lavoie B., Nausch B., Zane E. A. et al. Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease. Neurogastroenterol. Motil. 2012; 24 (7): e313-e324.
12. Cong P., Pricolo V., Biancani P., Behar J. Effects of cholesterol on CCK-1 receptors and caveolin-3 proteins recycling in human gallbladder muscle. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 299 (3): G742-G750.
13. Pasternak A., Matyja A., Gil K. Et al. Interstitial cajal-like cells and bile lithogenicity in the pathogenesis of gallstone disease. Pol. Przegl. Chir. 2013; 85 (6): 311–316.
14. Pasternak A., Matyja A., Gil K. Et al. Evidence of interstitial Cajal-like cells in human gallbladder. Folia Histochem. Cytobiol. 2012; 50 (4): 581–585.
15. Гаус О. В., Ахмедов В. А. Клинико-биохимические и иммунологические особенности желчнокаменной болезни, ассоциированной с метаболическим синдромом. Вестник НГУ. Серия: Биология, клиническая медицина. 2013; 11 (3): 125–129.
16. Гаус О. В., Ахмедов В. А. Иммунологические параллели в течении метаболического синдрома, ассоциированного с желчнокаменной болезнью. Фундаментальные исследования. 2013; 7: 51–54.
17. Lorenzo M., Fernández-Veledo S., Vila-Bedmar R. Et al. Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J. Anim. Sci. 2008; 86 (14): E 94–104.
18. Shih D. M., Yu J. M., Vergnes L. et al. PON 3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis. FASEB J. 2015; 29 (4): 1185–1197.
19. Yuan L., Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J. Hepatol. 2015; 7 (28): 2811–2888.
20. Forman B. M., Goode E., Chen J. Et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995; 81 (5): 687–693.
21. Fuchs C. D., Traussnigg S. A., Trauner M. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. Semin. Liver Dis. 2016; 36 (1): 69–86.
22. Гаус О. В., Ахмедов В. А. Динамика клинико-лабораторных и сонографических параметров при успешной консервативной литолитической терапии у больных желчнокаменной болезнью в ассоциации с метаболическим синдромом. Экспериментальная и клиническая гастроэнтерология. 2015; 119 (7): 18–23.
23. Lee J. M., Hyun J. J., Choi I. Y. et al. Comparison on Response and Dissolution Rates Between Ursodeoxycholic Acid Alone or in Combination With Chenodeoxycholic Acid for Gallstone Dissolution According to Stone Density on CT Scan: Strobe Compliant Observation Study. Medicine (Baltimore). 2015; 94 (50): e2037.
24. Ibrahim Z. S. Chenodeoxycholic acid increases the induction of CYP1A1 in HepG2 and H4IIE cells. Exp. Ther. Med. 2015; 10 (5): 1976–1982.
25. Di Ciaula A., Wang D. Q., Portincasa P. Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert. Rev. Gastroenterol. Hepatol. 2019; 13 (2): 157–171.
26. Ouyang H., Mei X., Zhang T. et al. Ursodeoxycholic acid ameliorates diabetic retinopathy via reducing retinal inflammation and reversing the breakdown of blood-retinal barrier. Eur. J. Pharmacol. 2018; 840: 20–27.
27. Kawamata Y., Fujii R., Hosoya M. et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003; 278 (11): 9435–9440.
28. Pols T. W., Nomura M., Harach T. et al. TGR 5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011; 14 (6): 747–757.
29. Katsuma S., Hirasawa A., Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR 5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005; 329 (1): 386–390.
30. Chen Y. S., Liu H. M., Lee T. Y. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. Cells. 2019; 8 (3). pii: E 253.
31. Machado FHF, Castro Filho HF, Babadopulos RFAL et al. Ursodeoxycholic acid in the prevention of gallstones in patients subjected to Roux-en-Y gastric bypass1. Acta Cir Bras. 2019 Feb 14; 34 (1): e20190010000009.
32. Рекомендации научного общества гастроэнтерологов России по диагностике и лечению желчнокаменной болезни. Экспериментальная и клиническая гастроэнтерология. 2012; 4: 114–123.
Review
For citations:
Akhmedov V.A., Gaus O.V. Modern views on development mechanisms and tactics for treatment of patients with gallbladder disease associated with metabolic syndrome. Medical alphabet. 2019;2(13):52-56. (In Russ.) https://doi.org/10.33667/2078-5631-2019-2-13(388)-52-56
Views:
624
Email this article 